-+ 0.00%
-+ 0.00%
-+ 0.00%

Tango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026

Benzinga·10/16/2026 11:05:11
Listen to the news

Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) Congress 2026, which will be held October 23-27, 2026 in Madrid, Spain.

Abstracts will be available on the ESMO website on Monday, October 19, 2026,12:05 am CEST. The data cutoff in the abstract is as of April 3, 2026. The poster presentation will include updated data.